A Phase 1, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors

Trial Profile

A Phase 1, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Dec 2017

At a glance

  • Drugs Talimogene laherparepvec (Primary)
  • Indications Adenocarcinoma; Breast cancer; Colorectal cancer; Gastric cancer; Liver cancer; Liver metastases; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 06 Nov 2017 Planned End Date changed from 14 Feb 2023 to 31 Mar 2023.
    • 06 Nov 2017 Planned primary completion date changed from 7 Sep 2021 to 22 Oct 2021.
    • 27 Jun 2017 Planned End Date changed from 1 Dec 2019 to 14 Feb 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top